Sparsentan is under clinical development by Travere Therapeutics and currently in Phase III for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData, Phase III drugs for Focal Segmental Glomerulosclerosis (FSGS) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Sparsentan LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sparsentan overview

Sparsentan (Filspari) belongs to biphenyls and derivatives. It is formulated as film coated tablets for oral route of administration. Filspari is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greaterthan or equal to1.5 g/g.

Sparsentan (RE-021, PS-433540) is under development for the treatment of immunoglobulin A vasculitis (IgAV), ANCA-associated Vasculitis, alport syndrome (AS), focal segmental glomerulosclerosis and IgA nephropathy (Berger's disease). It is administered by the oral route.RE-021 is a dual-acting receptor antagonist (DARA) that targets the angiotensin II receptor type 1 (AGTR1) and endothelin A receptor (ETA). It was also under development for the treatment of hypertension, metabolic disease.

Travere Therapeutics overview

Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with liver, rare kidney and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.

For a complete picture of Sparsentan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.